Transcription of Decisions With Patients and Families Regarding Aducanumab ...
{{id}} {{{paragraph}}}
Example: bankruptcy
Decisions With Patients and Families Regarding Aducanumab ...
Neurology Publish Ahead of PrintDOI: Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement Neurology Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes. Copyright 2021 american academy of Neurology. Unauthorized reproduction of this article is prohibited Published Ahead of Print on November 17, 2021 as Author(s): Winston Chiong, MD PhD1; Benjamin David Tolchin, MD MS2; Richard J Bonnie, LLB3; Katharina Busl, MD MS4; Salvador Cruz-Flores, MD5; Leon G Epstein, MD6; Ericka P Greene, MD7; Judy Illes, CM PhD8; Matthew Kirschen, MD PhD9; Daniel G Larriviere, MD JD10; Sneha Mantri, MD11; Michael A Rubin, MD12; Barney J.
Nov 17, 2021 · The American Academy of Neurology aims to support clinicians, patients and families in navigating these challenging decisions. In this position statement, we examine specific ethical considerations bearing on use of aducanumab based on a widely-accepted framework of principles in biomedical ethics,9 and offer recommendations for informed consent.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: